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Abstract
The inhibition of the DNA damage response (DDR) pathway in the treatment of cancers has recently reached an
exciting stage with several cell cycle checkpoint inhibitors that are now being tested in several clinical trials in
cancer patients. Although the great amount of pre-clinical and clinical data are from the solid tumor experience,
only few studies have been done on leukemias using specific cell cycle checkpoint inhibitors. This review aims to
summarize the most recent data found on the biological mechanisms of the response to DNA damages highlighting
the role of the different elements of the DDR pathway in normal and cancer cells and focusing on the main genetic
alteration or aberrant gene expression that has been found on acute and chronic leukemias. This review, for the first
time, outlines the most important pre-clinical and clinical data available on the efficacy of cell cycle checkpoint
inhibitors in single agent and in combination with different agents normally used for the treatment of acute and
chronic leukemias.
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Background
The DNA damage response (DDR) pathway
In the eukaryotic cells, the mechanism of response to
DNA damages is generally termed DNA damage re-
sponse (DDR) pathway (Fig. 1). The crucial function
of the DDR pathway is to maintain genomic stability
and to prevent tumor transformation. This pathway
includes different regulators involved in the recogni-
tion of DNA damage (DNA damage sensors), in the
recruitment of proteins on the site of DNA damages
(DNA damage mediators) and in the response to
DNA damages (DNA damage effectors) [1]. Three are
the most important consequences of the DDR activa-
tion: (i) the regulation of the cell cycle, throughout
the activation of different cell cycle checkpoints, (ii)
the activation of the mechanisms of DNA repair and
(iii) the induction of the apoptosis when the errors
are too extended to be fixed.
DNA damage sensors and mediators
Several deleterious attacks from extrinsic agents, such as
ionizing radiations or genotoxic agents, as well as intrin-
sic sources, such as reactive oxygen species (ROS), can
mine the DNA stability. In eukaryotic cells, appropriate
intracellular levels of ROS play a crucial role in regulat-
ing several biologic processes. On the other hand, exces-
sive production of ROS (due to primary oxidative
metabolism in the mitochondria, metabolic processes,
and inflammation) or inadequacy in a normal cell’s anti-
oxidant defense system can cause oxidative stress and,
eventually, DNA damages (ROS directly damages on
DNA structure or base modification). Independently
from the intrinsic or extrinsic sources, different types of
DNA damage can be recognized, like adduction, strand
torsions, or single breaks; however, the most deleterious
are the double-strand breaks (DSBs) that arise when
both the DNA strands are lesioned. Although DSBs are
physiologically generated (i.e., immunoglobulin re-
arrangement or as a consequence of controlled oxidative
metabolism), uncontrolled DSB generation is associated
with genetic instability [2, 3]. Due to their high cytotox-
icity, the generation of DSBs is the basis for conventional
chemotherapy currently used in the treatment of
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different kinds of cancer [4]. Three kinases, members of
the phosphoinositide three-kinase-related kinase (PIKK)
family, the DNA-dependent protein kinase (DNA-PK),
the ataxia-telangiectasia mutated (ATM), and the ATM
and Rad3 related (ATR) have a relevant biological role in
the initial phase of the DDR. In particular, both DNA-
PK and ATM are involved in the response to DSBs while
ATR is mostly involved in the response to DNA replica-
tion stress and in particular in the resolution of damages
that involve only one strand of the DNA structure
(single-strand breaks, SSBs) [5, 6]. In eukaryotic cells,
the Mre11-Rad50-Nbs1 (MRN) complex is fundamental
for the response to DSBs, for the localization of the
sites of damages and for the activation of ATM itself.
Indeed, it has been demonstrated that mutations,
down-expression, degradation, or mislocalization of
MRN components deeply affects ATM functionality
[7–9]. MRE11 is a protein structurally composed by a
Mn2+/Mg2+-dependent phosphoesterase domain and
two DNA-binding domains [10]. The main function of
MRE11 is to bind the DNA and, thanks to an exo-
and endonuclease activity, to synapse the DNA ends
[11]. RAD50 is a protein structurally homolog to a
group of proteins involved in “the maintenance of the
higher order structure of chromatin” called, SMC fam-
ily proteins. The function of RAD50 is to maintain the
DNA ends in close proximity thanks to an ATPase ac-
tivity [12]. The third member of the MRN complex,
NBS1, recruits different DNA repair and cell cycle
checkpoint proteins (ATM itself ) in the site of DNA
damages [13]. In general, due to their central role in
the early phase of the DSBs response, the members of
the MRN complex are always present during the dif-
ferent phases of the cell cycle and are localized in a
nuclear compartment known as promyelocytic leukemia
(PML) bodies [14]. In presence of DSBs, MRN members
rapidly, within seconds, delocalize from the PML bodies
to the site of damages. Also, ATM is constitutively
present in the nucleus of eukaryotic cells as an inactive
dimer. In presence of DNA damages, ATM dissociates in
active monomers and rapidly auto-phosphorylates mul-
tiple serine residues (Ser367, Ser1893, Ser1981, and
Ser2996) to avoid the reconstitution of the inactive dimer
[15, 16]. Further, post-transcriptional modifications like
the acetylation of a lysine residue (Lys3016) and the
phosphorylation of an additional threonine residue
(Thr1885) complete the stabilization and the activation
process [16]. ATM recruitment has been shown to re-
quire its binding to the C-terminus of NBS1, which is
fundamental also for the kinase activity of ATM. When
ATM is associated to the sites of damage, it rapidly phos-
phorylates the histone variant H2AX (ser139). This is a
key event of both ATM and ATR transduction pathways
and is necessary to amplify the signal of DNA damages
and to facilitate the recruitment of other mediators of the
DDR. Following the detection of a damage, ATM plays a
central role in the activation of the G1/S cell cycle check-
point, which prevents cells with damaged DNA from
starting the S phase. This mechanism that will be better
explained in the further section is primarily mediated
Fig. 1 Schematic representation of the DNA damage response (DDR) pathway. DNA damages are sensed and repaired in multi-protein complexes.
Signaling caused by this damage results in the activation of different mediators of the damage response and then results in cell cycle arrest and a
choice between repair or progression to apoptosis
Ghelli Luserna di Rora’ et al. Journal of Hematology & Oncology  (2017) 10:77 Page 2 of 14
through activation of the tumor suppressor protein p53
and of the checkpoint kinase 2 (CHK2). Single-strand
DNA (ssDNA) is physiologically generated during DNA
replication in all proliferating cells. Indeed, during the S
phase, replication blocks are generated to allow the DNA
polymerase to duplicate the two strands of DNA. The
first event for the generation of the replication blocks is
the activation of the replicative elicase; MCM (mini-
chromosome maintenance) that ahead of the polymerase
unwinds the double chain of DNA, generating ssDNA.
Single strands are extremely fragile. Different insults can
mine the stability of the replication forks, like the expos-
ure to UV ray, causing the break of one strand and, con-
sequently, generating SSBs. During DNA replication, the
replicative blocks are keeping opened thanks to the activ-
ity of proteins termed replication protein A (RPA). These
proteins bind the ssDNA and prevent the reconstitution
of double helix. The first step of the response to SSB is
the activation of ATR-interacting protein (ATRIP), the
regulatory partner of ATR, directly binds RPA, thereby
allowing the ATR–ATRIP complex to recognize the
RPA-ssDNA at DNA damage sites or stressed replication
forks [17]. The activation of ATR is strictly associated
with the constitution of the ssDNA-RPA complex [18].
Then, the complex ATR-ATRIP-ssDNA-RPA stimulates
the binding to the damage sites of second critical group
of proteins, the RAD17/RFC2-5 clamp-loader complex.
Consequently, the site of damage recruited the RAD9/
HUS1/RAD1 (9–1–1) heterotrimer that in turn recruits
topoisomerase II binding protein 1 (TopBP1) which acti-
vates ATR [19]. Recent studies have clarified on how
TopBP1 engages and stimulates the ATR-ATRIP complex
on RPA-ssDNA. Two independent studies showed that
ATR is phosphorylated on a threonine residue (Thr1989)
in the FAT domain after DNA damage, and this event is
dependent to ATIP, RPA, and ATR itself activity [20, 21].
The interactions between TopBP1 and the ATR-ATRIP
complex are believed to lead to conformational changes
of the kinase that increases the activity of its kinase do-
main and/or its binding to substrates [22]. Once acti-
vated, ATM and ATR delay the cell cycle progression
allowing the cells to resolve DNA damages before con-
tinuing the cell replication (Fig. 2).
DNA damage effectors
Different effectors are substrates of ATM and ATR ki-
nases, and most of them are involved in cell cycle regu-
lation (cell cycle checkpoint kinases) and in the
mechanisms of DNA repair. Here, we will focus on the
cell cycle regulation ATM/ATR-mediated. The most
Fig. 2 DNA damages sensor and mediators in the response to DSBs and SSBs. DNA damages trigger the recruitment of specific damage sensor
protein complexes. On one hand, the MRN (MRE11–RAD50–NBS1) complex is required for the activation of ataxia-telangiectasia mutated (ATM) in
response to double-strand breaks (DSBs). On the other hand, the ATM- and Rad3-related (ATR)-interacting protein (ATRIP) complex, formed by
ATR-ATRIP-9-1-1 complex, is recruited to sites of single-strand breaks and activates ATR. The activation of ATM and ATR promotes respectively the
activation of two different effectors, CHK2 and CHK1. Although currently, the activator of WEE1 is unknown, it is believed that CHK1 promotes
WEE1 activation
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important substrates of ATR and ATM are the check-
point kinase 1 (CHK1) and 2 (CHK2), respectively.
CHK1 kinase is activated by ATR through the phosphor-
ylation on serine 317 (ser317) and on serine 345
(ser345). Rapidly, CHK1 auto-phosphorylates on serine
296 stabilizing its structure and creating a binding site
for the interaction with its direct substrates, the phos-
phatases CDC25 (CDC25A/B/C). The activation of
CHK2 is enhanced by ATM through the phosphoryl-
ation on threonine 68 (thr68) and followed by several
auto-phosphorylation events. CHK2 shares the substrate
homology with CHK1 and inhibits CDC25A/B/C phos-
phatases in a similar way [23]. In eukaryotic cells, the
cell cycle is finely regulated by the oscillation in the ac-
tivity of different cyclin-dependent kinases, CDKs, which
are positively regulated by proteins, called cyclins, and
negatively regulated by CDK inhibitors (CDKI) and by a
mechanisms of inhibitory phosphorylation [24, 25]. The
transition from a phase of the cell cycle to another is
regulated by different cell cycle checkpoints and in par-
ticular by the G1/S (transition through the G1 phase to
the S phase), the intra-S and the G2/M checkpoints
(transition to the G2 phase and entry in the mitosis).
The activation of the G1/S checkpoint is mainly regu-
lated through the activity of the tumor suppressor p53
which has been showed to be one of the direct substrate
of ATM/ATR activation via the phosphorylation on
serine 15 (ser15). Different sequential phosphorylations
contribute to p53 stabilization and prevent the ubiquiti-
nation and consequently degradation enhanced by the
negative regulator of p53, MDM2 [26]. The regulation of
p53 in the G1/S checkpoint is also related to the activation
of two direct substrates of both ATM and ATR, respect-
ively, the checkpoint kinase 2 (CHK2) and the checkpoint
kinase 1 (CHK1), that promote the activatory phosphoryl-
ation of p53 on serine 20 (ser20) [27, 28]. Once fully acti-
vated, p53 promotes the transcription of different genes
involved in cell cycle regulation, like CDKN1A (cyclin-
dependent kinase inhibitor 1A (P21, Cip1)), and induction
of apoptosis, like BAX/PUMA/NOXA proteins [29]. The
transition through the S phase is mainly regulated by a
specific phosphatase, CDC25A [30]. This protein is neces-
sary to remove the inhibitory phosphorylation on tyrosine
15 (tyr15) and threonine 14 (thr14) on cyclin-dependent
kinase 2 (CDK2, CDC1). During normal replication,
CDC25A activates CDK2 promoting the formation of the
complex CDK2-cyclin E/cyclin A necessary for the entry
into the S phase and for the DNA synthesis. In the pres-
ence of DNA damages, both CHK1 and CHK2 phosphor-
ylate CDC25A on serine 136 (ser136) promoting its
ubiquitination by SCF/TrCP ubiquitin ligase complex and
following proteasomal degradation. The inhibition of
CDC25A causes an S phase delay. Similar to the regula-
tion of the S phase, also, the transition from the G2 to the
M phase is strictly dependent on the activation of specific
phosphates and in particular on the activation of both
CDC25B and CDC25C. During the checkpoint activation,
CDC25B is phosphorylated at serine 323 (ser323), by
CHK1 and bound by 14-3-3 that blocks its catalytic activ-
ity [31, 32]. Both CHK1 and CHK2 negatively regulate
CDC25C via phosphorylation of a serine residue (ser216);
this event creates a site for the binding to 14-3-3 protein
resulting in its cytoplasmic sequestration and G2/M
checkpoint activation. The events that follow CDC25C se-
questration are similar to those follow CDC25A degrad-
ation. The segregation of this phosphatase in the
cytoplasm prevents its accumulation into the nucleus and
consequently the inactivation of a protein complex crucial
for the transition through the G2/M phase, the CDK1
(CDC2)-cyclin B complex. This complex is finely regu-
lated not only by CHK1 or CHK2 but also by two proteins
of the WEE1 family, WEE1, and MYT1. While both ki-
nases can inhibit CDK1 through the phosphorylation on
tyrosine 15 (Tyr15), MYT1 can also phosphorylate on
threonine 14 (thr14), which has been shown to negatively
regulate CDK1 as well. Thus, after the activation of the
G2/M checkpoint, CHK1, CHK2, and WEE1 cooperate to
negatively regulate CDK1 to prevent the formation of the
complex with the cyclin B [33]. Although the regulation of
WEE1 during normal cell cycle has been established [34],
the mechanisms by which WEE1/MYT1 are activated in
response to DNA damage in human is still not fully
understood [35]. During normal cell division polo kinase 1
(PLK1) phosphorylates WEE1 promoting its degradation
and, consequently, the beginning of mitosis. After DDR
activation, both ATM and ATR promote the inhibitory
phosphorylation of PLK1, leading to the nuclear accumu-
lation of WEE1 [36].
Cell cycle checkpoint-related proteins alteration in acute
and chronic leukemias
Although in normal cells the cell cycle checkpoint ki-
nases as well as other elements of the DDR pathway act
as tumor suppressor and are crucial for the maintenance
of genetic stability, in cancer, they have been found to
protect tumor cells from different stresses and, conse-
quently, to promote tumor progression [37]. Indeed, in
normal cells, DNA errors are fixed by the repair mecha-
nisms and if not, cell proliferation is arrested and cell
death often ensues. The following section summarizes
the main genetic alterations (mutations, copy number al-
teration, and gene expression alterations) that, although
rare, have been reported in leukemias.
Mutations and copy number alterations in key cell cycle
checkpoint genes in leukemias
The loss of function of ATM leads to the genetic disorder
ataxia-telangiectasia (A-T), characterized by cerebellar
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degeneration, immunodeficiency, radiation sensitivity,
chromosomal instability, and cancer pre-disposition
[38, 39]. Mutations in ATM pre-dispose A-T patients to
the development of lymphoid neoplasms, with a risk for
leukemia approximately 70 times higher than the normal
population [40]. Inactivating mutations and copy number
alterations have been reported in both acute and chronic
leukemia subtypes. In acute leukemia, Haidar and col-
leagues reported a high frequency of ATM deletions (10
out of 36; 28%), including 7 (19.4%) cases with loss of het-
erozygosity (LOH) and 3 (8.4%) cases with homozygous
deletions in adult acute lymphoblastic leukemia (ALL) pa-
tients. Interestingly, in the ALL subgroup, the ATM pro-
tein deficiency (due to LOH or homozygous deletions)
correlates with a favorable prognosis [41]. Copy number
gains of ATM in 3 out of 191 (1.6%) adult patients with de
novo acute myeloid leukemia (AML) have been reported
by the Cancer Genome Atlas Research Network [42]. In
chronic myeloid leukemia (CML), ATM was investigated
as a potential candidate gene for the increased genetic in-
stability following the evolution from chronic phase to
blasts crisis (BC). Initial mutational analysis of 57 CML
cases in BC highlighted no deleterious nucleotide changes
in ATM and lack of correlation with BC progression [43].
However, the correlation between the loss of ATM and the
acceleration of BC has been recently reported in CML
mouse models [44]. LOH events involving the ATM locus
and ATM protein deficiency occur in 14% and 34%, re-
spectively, of patients with chronic lymphocytic leukemia
(CLL) and have been found to correlate with aggressive
disease and worse outcome [45]. Recent studies in large
cohorts of CLL primary samples revealed a high frequency
of missense/truncating mutation of ATM and deletion of
ATM (associated with 11q22.3-23.2 deletion) [46–48]. ATR
mutations, as well as copy number alterations, are rare in
tumor cells due to the fundamental biological role of this
kinase. Currently, no mutations affecting ATR have been
annotated in acute and chronic leukemia patients, and only
one case of single-nucleotide variant (SNV) out of 50 sam-
ples has been described in AML patients [49]. The down-
stream target of ATM, CHK2, has been found instead
mutated in low rate in several kinds of cancer and in par-
ticular in hereditary cancers (CHK2 1100delC protein-
truncating mutation confers a twofold increased risk of
breast cancer) [50, 51]. In both acute (AML) and chronic
(CLL) leukemias, only few studies reported mutations or
copy number alterations of CHK2 and with a very low per-
centage [52–54]. Similarly to ATR, no mutations have been
reported in CHK1 in acute and chronic leukemias.
Gene expression alteration of key cell cycle checkpoint
genes in leukemia
In highly proliferating tumor cells, the activation of dif-
ferent oncogenes causes the so called replicative stress
and, consequently, the activation of different elements of
the DDR [55, 56]. This phenomenon has been thought
to participate in the early phases of tumor progression
and, at least in solid tumors, with the development of
pre-neoplastic lesions. In particular, the dysregulation of
DDR-related genes together with the activation of spe-
cific oncogenes is responsible for the high genetic in-
stability that characterizes acute leukemia. Different
groups have reported that the activation of oncogenes,
like MYC, BCR-ABL1, and FLT3/ITD, alters the expres-
sion of different genes involved in the response to DNA
damages. Today is generally believed that MYC-driven
cells in order to sustain the high proliferative state in-
duced by MYC itself need to up-regulate the expression
of genes involved in both ATR/CHK1 and ATM/CHK2
pathway. In particular, in MYC-driven B cell lymphomas,
the hyper-activation of the ATR/CHK1 pathway is
thought to be fundamental to protect the replicative
forks from collapse [57, 58]. MYC has been found over-
expressed not only in lymphoma cells but also in chronic
myeloid leukemia (CML) patients [59], in ALL patients
harboring the translocations t(8;14), t(8;22), and t(2;8)
[60] and in AML [61]. In a recent study, Muvarak and
colleagues showed that in BCR-ABL1 and FLT3/ITD-
positive leukemia cells, the constitutive activation of
these kinases, via the overexpression of MYC, triggers
intracellular pathways that increase genomic instability
through generation of ROS, DSBs, and error-prone re-
pair [62]. A study from Cavelier C. and colleagues
showed that in primary AML samples with complex
karyotype, the level of DNA damage detected by
phospho-H2AX as well as the level of activated CHK1 is
higher than in AML samples with normal karyotype and
in normal hematopoietic precursors [63]. In ALL, differ-
ent studies have confirmed the overexpression of the
kinase CHK1 in leukemic blasts in comparison with its
expression in normal lymphoid precursors [64, 65].
Moreover the ATR/CHK1 pathway has been found to
protect BCR-ABL1-positive leukemic cells from the
cytotoxicity of conventional therapies, slowing the cell
cycle progression and allowing the leukemic cells to re-
pair the DNA damages induced by the therapeutic treat-
ment [66] (Fig. 3).
Cell cycle checkpoint kinase inhibitors against leukemias
Due to the central role in the DNA damage response,
different cell cycle checkpoint inhibitors (ATM/ATR/
CHK1/CHK2/WEE1 inhibitors) have been developed to
specifically inhibit the mechanisms by which tumor cells
respond to DNA damaging agents. Initially, this class of
compounds has been developed for the treatment of p53
mutated tumors because of their impaired G1/S check-
point, and then, their applicability has been extended
also to p53 wild-type tumors [42, 43]. These compounds
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have been developed to potentiate the efficacy of differ-
ent chemotherapeutic compounds especially for the
treatment of solid tumors [44]. The following section
summarizes the main studies that have been performed
to explore the efficacy of different cell cycle checkpoint
inhibitors in acute (ALL and AML) and chronic (CLL
and CML) leukemias.
ATM/ATR inhibitors against leukemias
ATM inhibitors KU-55933 was the first developed
potent ATM inhibitor (KuDOS Pharmaceuticals,
AstraZeneca). Hickinson and colleagues showed that
KU-55933 confers marked sensitization to ionizing ra-
diation and DNA DSB-inducing chemotherapeutics,
such as the topoisomerase II inhibitors (etoposide and
doxorubicin), in cancer cells [67]. The efficacy of KU-
55933 against leukemic cells was evaluated in Jurkat
cells with or without etoposide. The combination between
the DSBs inducer and the ATM inhibitor deeply affected
the cell viability of the leukemic cells [68]. Although KU-
55933 showed strong efficacy in vitro, its high lipophilicity
limited the use in in vivo studies.
KU-59403 is a novel ATM inhibitor with improved po-
tency, solubility, and bioavailability over the KU-55933.
Batey and colleagues demonstrated a good tissue distri-
bution and a good efficacy in mice [69]. In acute
leukemia, Grosjean-Raillard and colleagues demon-
strated that treatment with KU-59403 represses the
antiapoptotic transcription factor nuclear factor-κB
(NF-κB) pathway, which has been found to be consti-
tutively activated in CD34+ myeloblasts of high-risk
myelodysplastic syndrome (MDS) and AML patients
and consequently, it induces cell death via apoptosis
[70]. Despite none clinical trials have been yet per-
formed using ATM inhibitors, the results of several in
vitro studies carried out that the pharmacological
inhibition of this protein has great potential as a
cancer therapy in combination with radiotherapy or
certain chemotherapeutic drugs (like topoisomerase
inhibitors).
ATR inhibitors Schisandrin B was the first ATR-
selective small molecule inhibitor that has been evalu-
ated in vitro. Nishida and colleagues reported that schi-
sandrin B was able to abrogate UV-induced intra-S
phase and G2/M cell cycle checkpoints and increase the
cytotoxicity of UV radiation in human lung cancer cells
[71]. Then, Vertex Pharmaceuticals using a large high-
throughput screening led to the discovery of the first
series of both potent and selective ATR kinase inhibitors
[72]. The first selective ATR inhibitor, VE-821, had
>100-fold selectivity for ATR versus ATM, PI3K, DNA-
PK, and mTOR and sensitized leukemic cell lines to
radiotherapy [72, 73].
VE-822 (VX-970), a further analogs of VE-821, has
been improved with increased solubility, potency, select-
ivity, and pharmacodynamic properties [74]. Several pre-
clinical studies have shown that VX-970 robustly
Fig. 3 The DDR pathway in cancer cells. The high proliferation rate induced by different oncogenes (MYC or BCR-ABL1) can led to the so called
replicative stress which is a negative signal for proliferation. In order to sustain the replicative stress and continue to proliferate, leukemic cells
need to up-regulate different key elements of the DDR pathway, like CHK1. The two most important consequences of DDR elements up-regulation are
(1) genetic instability due to the increment of tolerable level of DNA damages and (2) resistance to DNA damaging agents, such as chemotherapies,
due to the up-regulation of the mechanisms involved in the DNA repair
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sensitizes multiple tumor cell lines to cisplatin, ionizing
radiation, gemcitabine, PARP inhibitors, topoisomerase I
inhibitors, etoposide, and oxaliplatin in vitro [75–80]. In
vivo studies using both VE-821 and VX-970 showed ro-
bust results. Indeed, these two ATR inhibitors synergized
with radiotherapy and gemcitabine in pancreatic cancer
xenograft models [76, 77] and with irinotecan in a colo-
rectal cancer model [79]. Nowadays, different clinical tri-
als are ongoing against solid tumors to assess the safety,
tolerability, and pharmacokinetics of VX-970 in combin-
ation with cytotoxic chemotherapy (NCT02157792,
NCT02595931, NCT02567422, and NCT02595892).
AZD6738 is the second ATR inhibitor currently in
clinical development that possesses significantly im-
proved solubility bioavailability and pharmacokinetic
properties compared to other ATR inhibitors and is suit-
able for oral dosing [81]. Treatments with AZD6738 in-
hibit the phosphorylation of CHK1 while increasing
phosphorylation of γH2AX in vitro. In in vivo models,
combinatorial studies with carboplatin or ionizing radi-
ation (IR) demonstrated significantly reduction of tumor
progression in comparison with the effects of the single
treatments [81, 82]. In hematological malignances,
AZD6738 showed activity as monotherapy in mantle cell
lymphoma xenograft mouse models with ATM and p53
deficiencies [83] and in primary CLL patient-derived xe-
nografts with 11q deletion (ATM deficient) and 17p de-
letion (p53 deficient) [84]. Finally, preliminary data
highlighted that AZD6738 synergizes with carboplatin,
bendamustine, and cyclophosphamide in an ATM-
deficient diffuse large B cell lymphoma model. Currently,
no data have been published using ATR inhibitors in
acute leukemia.
CHK1/CHK2 inhibitors against leukemias
In the last decade, the number of publications evaluating
the pre-clinical and clinical efficacy of small molecule in-
hibitors of CHK1 has constantly grown [85] as well as
the number of molecules against this kinase [86, 87]
(Fig. 4). The first inhibitor of CHK1 was the UCN-01
(known as 7-hydroxystaurosporine). This molecule
showed to inhibit not only CHK1 but also other different
kinases (CHK2, CDK1, CDK2, PKC 7, and MK2) and to
promote the G2/M checkpoint override upon treatment
Fig. 4 Schematic representation of the mechanism of action of CHK1/CHK2 inhibitor. In both normal and tumor cells, the recognition of
damages on DNA by the DDR-sensors activates different cell cycle checkpoints. The central event of checkpoint activation is the inhibition of the
phosphatases CDC25s which is necessary for the activation of the complexes CDK-cyclins. Both ATR/CHK1 and ATM/CHK2 pathways promote
CDC25s inhibition (ubiquitin-dependent degradation) and, consequently, they arrest cell cycle in response to DNA damages. Tumor cells can
activate these pathways in response to DNA damaging agents and survive. The treatment with a CHK1/CHK2 inhibitor avoids the degradation of
the phosphatase CDC25s, inducing cell cycle progression even in the presence of DNA damages. For this reason, different CHK1/CHK2 inhibitors
have been developed to enhance the DNA damaging from chemotherapeutic drugs by inhibiting the cell cycle checkpoint negative signals
Ghelli Luserna di Rora’ et al. Journal of Hematology & Oncology  (2017) 10:77 Page 7 of 14
with DNA damaging agents such as cisplatin or topo-
isomerase inhibitor. UCN-01 was tested in several clin-
ical trials; however, the low specificity of the compound
caused many harmful side effects and this avoided its
progression beyond phase II clinical trials [88, 89].
MK-8776 (SCH900776) is a potent and selective
CHK1 inhibitor in clinical development. It rapidly, less
than 2 h, induced γH2AX accumulation and suppressed
CHK1 functionality (shown by the reduction of the
auto-phosphorylation site of serine 296). The efficacy of
this inhibitor was assessed not only in single agent but
also in combination with different genotoxic compounds
showing chemotherapy sensitization by increasing the
level of DSBs. Many other studies confirmed the great
efficacy of this compound for the treatment of differ-
ent kinds of tumor, and today, MK-8776 entered in
phase II clinical trials in combination with chemother-
apy [86, 90–92]. The efficacy of the compound was
also evaluated in hematological malignances. Day and
colleagues demonstrated that MK-8776 synergistically
potentiated the histone deacetylase (HDAC) inhibitor
(HDACI) vorinostat in both AML cell lines and primary
cells [92]. Moreover, they showed that efficacy of the com-
bination was independent on the mutational status of p53
and that the synergistic interactions were associated with
inhibition of CHK1 activity, interference with the intra-S
phase checkpoint, disruption of DNA replication, and
down-regulation of proteins involved in DNA replication
and repair [92]. Zemanova J. and colleagues reported that
SCH900776 enhanced the cytotoxicity of different nucleo-
side analogs (fludarabine, cytarabine, and gemcitabine) on
the p53-deficient CLL cell line MEC1 and primary cells
isolated from CLL patients [93].
AZD7762 is an ATP competitive CHK1/CHK2 inhibi-
tor. This compound was evaluated in different trials as a
chemo-sensitizer agent for conventional chemotherapy.
It has been described that lung cancer cells expressing
high levels of CHK1 were hyper-sensitive to AZD7762.
This suggests a correlation between CHK1 inhibitor-
mediated sensitivity and elevated amounts of CHK1. Dif-
ferent further studies were performed to investigate the
efficacy of ASD7762 in combination with different com-
pounds. Indeed, it has been reported that combination
of AZD7762 with gemcitabine and ionizing radiation
deeply sensitized pancreatic cells to radiation [94]. The
efficacy of the compound was evaluated also in
hematologic malignances, e.g., in different myeloma
multiple (MM) cell lines. The combination of AZD7762
with alkylating agents (melphalan) promoted apoptosis
and mitotic catastrophe of p53-mutated MM cells [95].
Moreover, Didier et al. showed that AZD7762 enhances
genotoxic treatment efficacy in immature KG1 AML cell
line and in AML primary leukemic cells [96]. In this
study, they also found a correlation between the
sensitivity to the checkpoint kinase inhibitors and a
complex karyotype, usually a poor prognostic marker to
conventional chemotherapy. Thus, the basal level of
DNA damage (γH2AX, CHK1, and phosphorylated
ATM/ATR substrates) could be a useful marker to select
AML patients susceptible to receive this type of combin-
ation therapy [96].
PF-0477736 is a selective and competitive inhibitor for
the CHK1 ATP site. Its specificity is 100 times stronger
for CHK1 than that for CHK2. The efficacy of this com-
pound has been well established against different kinds
of tumor. In ovarian cancer, it has been shown that
tumor cells strongly respond to treatment with PF-
0477736 but they generate metastasis and chemo-
resistant clones [97]. The efficacy of PF-0477736 has
been evaluated also in leukemia. Sarmento et al. [65]
demonstrated that the T-ALL primary samples express
higher level of CHK1 kinase in comparison to normal
thymocytes. The treatment with PF-0477736 promoted
apoptotic cell death and CHK1 inhibition and conse-
quently impaired replication and abrogation of G2/M
checkpoint in T-ALL cells. Interestingly, in vitro treat-
ment did not significantly affect the viability of normal
thymocyte cells [65]. Similar results have been shown by
our group. The inhibition of CHK1/CHK2 by PF-
0477736 as single agent deeply reduced the cell viability
of ALL primary cells and leukemia cell lines. The results
from the in vitro/ex vivo studies were further confirmed
using an in vivo model [64]. Recently, Nguyen T. and
colleagues reported the in vitro/in vivo synergic efficacy
of PF-00477736 in combination with the Src/ABL inhibi-
tor bosutinib (SKI-606) in BCR-ABL1-positive CML or
ALL cells, focusing on highly imatinib-resistant models
with ABL kinase mutations. The authors speculated that
the combination acts through a BCR-ABL1-independent
process that may involve multiple mechanisms, includ-
ing inactivation of ERK1/2 and Src, up-regulation of
BIM, down-regulation of MCL-1 (BCL-2-like protein),
activation of CDK1, and induction of DNA damage [98].
LY2603618, a potent and selective inhibitor of CHK1,
is the first second-generation checkpoint kinase inhibitor
that has been evaluated in a clinical trial [99]. King and
colleagues [100] reported that the treatment with
LY2603618 produced a cellular phenotype similar to that
reported for depletion of CHK1 by RNA interference
(RNAi). Moreover, they reported that the inhibition of
CHK1 caused impaired DNA synthesis, elevated H2AX
phosphorylation, and pre-mature entry into mitosis. Fi-
nally, they showed that LY2603618 was able to override
the G2/M checkpoint activated after the exposure to
doxorubicin, resulting in cells entering into metaphase
with poorly condensed chromosomes [100]. In several
studies, LY2603618 potentiated the effect of DNA dam-
age compounds like pemetrexed and cisplatin in vitro.
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This result was confirmed in vivo using a tumor xeno-
graft model and placed the bases for a phase I clinical
trial evaluating the effectiveness of LY2603618 in com-
bination with pemetrexed and cisplatin in patients with
advanced cancer [99]. Zhao J. and colleagues have re-
cently reported the efficacy of LY2603618 in combin-
ation with the BCL-2 inhibitor ABT-199 in AML cell
lines and primary cells (n = 26). The authors demon-
strated that the treatment with LY2606368 reduced
the total amount of MCL-1 and, consequently, en-
hanced the efficacy of ABT-199 in terms of induction
of apoptosis [101].
LY2606368 (prexasertib) is a novel CHK1/CHK2 in-
hibitor which has been reported to cause as a single
agent DBSs while simultaneously removing the protec-
tion of the DNA damage checkpoints. King and col-
leagues reported that LY2606368 increases extensive
DNA damage in the cell population in S phase highlight-
ing the possible mechanism of death through replication
catastrophe [102]. In a recent study from our group in
acute lymphoblastic leukemia, the efficacy of LY2606368
was evaluated both as single agent and in combination
with different compounds currently used in clinical
practice. This study showed that LY2606368 deeply
sensitized both primary and leukemic cells to the anti-
metabolite, clofarabine, and to tyrosine kinase inhibitors
(imatinib and dasatinib) [103].
WEE1 inhibitors against leukemias
Many WEE1 inhibitors have been developed to override
cell cycle checkpoint signaling and, consequently, to im-
prove the sensitivity of tumor cells to the toxic effect of
different genotoxic agents (Fig. 5). Several studies have
shown their efficacy in the treatment of different kinds
of tumor not only in combinatorial studies but also as
single agent. The PD0166285 is a non-selective kinase
inhibitor, which targets WEE1 but also CHK1, Myt1, c-
Src, PDGFR-, fibroblast growth factor receptor-1, and epi-
dermal growth factor receptor tyrosine kinases [104, 105].
This inhibitor has been shown to successfully inhibit
CDK1 phosphorylation (tyrosine 15 and threonine 14)
and to abrogate G2/M checkpoint after IR irradiation
in vitro.
MK-1775 (AZD1775) is the mostly studied WEE1 in-
hibitor. Several studies have shown that this inhibitor se-
lectively sensitizes p53-deficient cancer cells to the toxic
effect of gemcitabine, carboplatin, 5-fluorouracil, and
cisplatin [106–109]. The sensitizing activity of MK-1775
Fig. 5 Schematic representation of the mechanism of action of the WEE1 inhibitor. In both normal and tumor cells, the activation of WEE1 upon
induction of DNA damage is not fully understood. WEE1 phosphorylates both CDK1/CDK2 to prevent the constitution of the complexes CDK/
cyclins. Inhibition of WEE1 activity prevents the phosphorylation of CDKs and impairs the cell cycle checkpoint after DNA damage induction. This
may lead to apoptosis upon treatment with DNA damaging chemotherapeutic agents
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selectively on p53-deficient cells has been shown also
after gamma ray irradiation. Although all the above
mentioned studies, recent findings highlighted that the
effectiveness of this compound in different types of
tumor is independent on the functional status of p53
[110]. In hematological malignancies, recent studies
mainly on acute myeloid leukemia have shown the effi-
cacy of this compound, not only as single agent [111]
but also in combination with different compounds like
HDAC (vorinostat), CDK inhibitor (roscovitine),
LY2603618, or cytarabine [111–116]. The combination
of cytarabine and MK-1775 enhanced chemotherapy
cytotoxicity by abrogating the mechanisms of DNA re-
pair and by the inhibition of the S phase arrest induced
by cytarabine [110, 117]. Similar results were recently
found in T-ALL cell lines and in in vivo models [118].
Tibes and colleagues showed the efficacy of MK-1775 in
both CML primary cell and cell lines as single agent and
in combination with cytarabine. In this study, they
showed that the inhibition of WEE1 significantly sensi-
tizes leukemic cells to cytarabine in terms of reduction
of cell viability and induction of apoptosis [117]. These
data support the development of clinical trials including
AZD1775 in combination with conventional chemother-
apeutic compounds for leukemias.
Data available from clinical trials in solid tumors
A phase I dose-escalation study aiming to examine the
safety and tolerability of LY2603618 in combination with
pemetrexed 500 mg/m2 every 21 days in patients with
cancer defined a maximum tolerated dose (MTD) of
150 mg/m2. A following phase I study using LY2603618
in combination with gemcitabine in patients with solid
tumors showed that among the 50 patients enrolled, fre-
quent adverse events, possibly related to study drug
treatment, included fatigue (44%), decreased platelets
(42%), decreased neutrophils (32%), nausea (26%), and
decreased hemoglobin (20%). Systemic exposure of
LY2603618 increased dose dependently, while clearance
was relatively dose independent. The mean LY2603618
half-life varied. However, the durations were still suitable
for maintaining human exposures while minimizing ac-
cumulation. LY2603618 pharmacokinetic (PK) was not
altered by gemcitabine administration. Plasma exposures
that correlate with the maximal pharmacodynamic effect
in non-clinical models were achieved for all doses. One
patient with non-small cell lung cancer carcinoma
achieved a partial response; 22 patients had stable dis-
ease. They conclude that the MTD of LY2603618 com-
bined with gemcitabine was 200 mg/m2, but a fixed
LY2603618 dose of 230 mg combined with gemcitabine
was selected as the recommended phase II dose [99]. A
consequent phase II study evaluating the effect of
LY2603618 in combination with pemetrexed in patients
with advanced or metastatic non-small cell lung cancer
highlighted no significant improvement of pemetrexed
efficacy as single agent in non-small cell lung cancer
[119]. Until now, only a phase I study has been done
using LY2606368 as single agent in advanced solid tu-
mors. Forty-five patients were treated with two different
dose-escalation schedule: from 10 to 50 mg/m2 on
schedule 1 (days 1 to 3 every 14 days) or from 40 to
130 mg/m2 on schedule 2 (day 1 every 14 days); seven
experienced dose-limiting toxicities (all hematologic).
The MTDs were 40 mg/m2 (schedule 1) and 105 mg/m2
(schedule 2). The most common related grade 3 or 4
treatment-emergent adverse events were neutropenia,
leukopenia, anemia, thrombocytopenia, and fatigue.
Grade 4 neutropenia occurred in 73.3% of patients and
it was transient (typically <5 days). Febrile neutropenia
incidence was low (7%). The LY2606368 exposure over
the first 72 h (area under the curve from 0 to 72 h) at
the MTD for each schedule coincided with the exposure
in mouse xenografts that resulted in maximal tumor re-
sponses. Minor intra- and intercycle accumulation of
LY2606368 was observed at the MTDs for both sched-
ules. Two patients (4.4%) had a partial response. Fifteen
patients (33.3%) had a best overall response of stable dis-
ease (range, 1.2 to 6.7 months), six of whom had squa-
mous cell carcinoma. An LY2606368 dose of 105 mg/m2
once every 14 days is being evaluated as the recom-
mended phase II dose in dose-expansion cohorts for pa-
tients with squamous cell carcinoma. A phase I study of
single-agent AZD-1775 involving 25 patients with refrac-
tory solid tumors showed that the MTD was established
as 225 mg twice per day orally over 2.5 days per week
for 2 weeks per 21-day cycle. Confirmed partial re-
sponses were observed in two patients carrying BRCA
mutations: one with head and neck cancer and one with
ovarian cancer. Common toxicities were myelosup-
pression and diarrhea. The on-target efficacy of the
compound was assessed looking at the levels of phos-
phorylated Tyr15-Cdk (pY15-Cdk) and γH2AX in
paired tumor biopsies obtained at the MTD [120]. A sec-
ond phase I study demonstrated target inhibition (Tyr15-
Cdk) at MTD in combination with carboplatin adult
patients with advanced solid tumors (NCT00648648). Pa-
tients with p53 mutated ovarian cancer refractory or re-
sistant (<3 months) to standard first line therapy
(carboplatin plus paclitaxel) were re-exposed to carbopla-
tin (AUC 5), plus five bi-daily doses of 225 mg AZD-
1775 in a 21-day cycle (MTD). Bone marrow toxicity,
fatigue, diarrhea, nausea, and vomiting were the most
common adverse events. Out of 24 patients enrolled, 22
patients were evaluable for study endpoints. As best re-
sponse (RECIST 1.0), six patients (27%) showed con-
firmed partial response (PR) with a median progression-
free survival (PFS) of 10.9 months. Nine patients (41%)
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had stable disease and seven patients (32%) had progres-
sive disease as best response, with a median PFS of 5.3
and 1.3 months, respectively (NCT01164995).
Conclusions
Nowadays, the amount of pre-clinical data has con-
firmed the efficacy of different cell cycle checkpoint in-
hibitors against different kinds of hematologic as well as
solid tumors, as single agent, or in combination with a
wide number of drugs. The efficacy as well as the safety
of different combinations is now being established also
in several phase I/II clinical trials. Most of the studies
were based on the use of cell cycle checkpoint inhibitors
in combination with standard chemotherapy in order to
enhance its effectiveness. Although the good successes
that have been achieved have many questions needed to
be answered regarding the safety and the effectiveness of
this class of compounds. Some acute leukemia subtypes
are characterized by high genetic instability that should
make this kind of tumor very sensitive to cell cycle
checkpoint inhibitors. However, few clones can take ad-
vantage from the inhibition of DNA repair, acquire novel
invasive features, and start to proliferate. Long-period
safety of cell cycle checkpoint inhibitors should be ad-
dressed also in normal tissues in order to exclude tumor
transformation of healthy cells. A second crucial ques-
tion that should be answered, at least in hematological
malignances, is the ability of cell cycle checkpoint inhibi-
tors to eradicate leukemic stem cells in the contest of
bone marrow niche. Indeed, until today, very few studies
have addressed, for example, the efficacy of the check-
point inhibitors under hypoxic condition or more gen-
eral in experimental settings that mime the niche micro-
environment. Finally, prognostic markers should be eval-
uated to stratify patients that could be more sensitive to
checkpoint kinase inhibitors. One predictive marker
could be the evaluation of basal expression of elements
involved in the DDR and the level of genetic instability
(γH2AX expression). In our opinion, based on the re-
sults from the clinical trials, a last important question
should be answered: can we substitute DNA damaging
agents (chemotherapy) with DDR inhibitors in standard
therapeutic regimens in which a specific inhibitor, for
example, BCR-ABL1 inhibitors, is associated with con-
ventional chemotherapy? Several studies have been done
to evaluate the chemotherapy-induced genetic instability
in various types of cancers [121–123]. It is generally
believed that DNA damaging compounds can posi-
tively select tumor cells that harbor particular muta-
tions or can increase genetic instability leading to the
generation of novel clones with more aggressive phe-
notypes. These two scenarios are the biological expla-
nations for the failure of standard chemotherapy and
for tumor relapses. For the abovementioned reasons,
we speculate that a winning strategy to avoid relapse
may be to substitute chemotherapy with cell cycle
checkpoint inhibitors in the treatment of hematological
malignances that can be treated with specific targeted
inhibitors.
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